Difference between revisions of "Ondansetron"
From WikiAnesthesia
Cornel Chiu (talk | contribs) (Brief summary, Uses, contraindication, precautions, pharmacodynamics, adverse effects, chemistry and formulation, references) |
Cornel Chiu (talk | contribs) (Right template) |
||
| Line 6: | Line 6: | ||
| contraindications = Prolonged QT intervals, patients taking apomorphine | | contraindications = Prolonged QT intervals, patients taking apomorphine | ||
| routes = PO, IM, IV | | routes = PO, IM, IV | ||
| dosage = | | dosage = Postoperative nausea and vomiting | ||
Adults: | |||
- 8 mg every 12 hours PO | |||
- 4 mg IV | |||
Maximum dose of 16 mg; 8 mg in severe hepatic impairment | |||
Pediatrics: | |||
- 0.15 mg/kg per dose with maximum of 16 mg per dose | |||
| dosage_calculation = ondansetron | | dosage_calculation = ondansetron | ||
| mechanism = 5HT3 antagonist | | mechanism = 5HT3 antagonist | ||
| Line 22: | Line 28: | ||
* treatment and prevention of radiation induced nausea and vomiting | * treatment and prevention of radiation induced nausea and vomiting | ||
* Prevention of postoperative nausea and vomiting | * Prevention of postoperative nausea and vomiting | ||
* | * Off-label use for the prevention of nausea and vomiting associated with pregnancy<ref name=":0">{{Citation|last=Griddine|first=Alexandria|title=Ondansetron|date=2022|url=http://www.ncbi.nlm.nih.gov/books/NBK499839/|work=StatPearls|place=Treasure Island (FL)|publisher=StatPearls Publishing|pmid=29763014|access-date=2023-01-05|last2=Bush|first2=Jeffrey S.}}</ref> | ||
== Contraindications<!-- List contraindications and precautions for use of the drug. --> == | == Contraindications<!-- List contraindications and precautions for use of the drug. --> == | ||
| Line 52: | Line 58: | ||
* Antagonism of the 5HT<sub>3</sub> receptors | * Antagonism of the 5HT<sub>3</sub> receptors | ||
* Centrally, ondansetron antagonizes the 5HT<sub>3</sub> receptors in the area postrema <ref name=":0" /> | * Centrally, ondansetron antagonizes the 5HT<sub>3</sub> receptors in the area postrema <ref name=":0" /> | ||
* Peripherally, ondansetron antagonizes the 5HT<sub>3</sub> receptors on the vagus nerve within the GI tracts which forms synapses within the nucleus tracts solitarius | * Peripherally, ondansetron antagonizes the 5HT<sub>3</sub> receptors on the vagus nerve within the GI tracts which forms synapses within the nucleus tracts solitarius <ref name=":0" /> | ||
** Predominant mechanism for its anti-emetic effect | ** Predominant mechanism for its anti-emetic effect | ||
Revision as of 15:31, 5 January 2023
Ondansetron
| Trade names |
Zofran |
|---|---|
| Clinical data | |
| Drug class |
Anti-emetic |
| Uses |
Prevention and treatment of chemo-induced, radiation induced nausea and vomiting, prevention of postoperative nausea and vomiting |
| Contraindications |
Prolonged QT intervals, patients taking apomorphine |
| Routes of administration |
PO, IM, IV |
| Dosage |
Postoperative nausea and vomiting Adults: - 8 mg every 12 hours PO - 4 mg IV Maximum dose of 16 mg; 8 mg in severe hepatic impairment Pediatrics: - 0.15 mg/kg per dose with maximum of 16 mg per dose |
| Dosage | |
| Pharmacodynamics | |
| Mechanism of action |
5HT3 antagonist |
| Adverse effects |
cardiac arrhythmias, cardiac arrest, constipation, headaches |
| Pharmacokinetics | |
| Metabolism |
Liver oxidation followed by glucuronidation and sulfate conjugation |
| Elimination half-life |
4 hours |
| Physical and chemical data | |
| Article quality | |
| Editor rating | |
| User likes | 0 |
Ondansetron is a 5HT3 receptor antagonist that is commonly used for the treatment and prophylaxis of chemo induced nausea and vomiting, radiation induced nausea and vomiting, and postoperative nausea and vomiting.
Uses
- treatment and prevention of chemo-induced nausea and vomiting
- treatment and prevention of radiation induced nausea and vomiting
- Prevention of postoperative nausea and vomiting
- Off-label use for the prevention of nausea and vomiting associated with pregnancy[1]
Contraindications
Absolute contraindications
- Prolonged QT intervals
- Patients taking apomorphine [1] as it can cause hypotension and loss of consciousness
Precautions
- Maximum dose of 16 mg IV due to risk of QT prolongation and arrhythmias
- Maximum dose decreased to 8 mg IV or 8 mg PO in severe hepatic impairment
- Dissolving tablets formulations contain phenylalanine which can lead to irreversible neurological damage in phenylketonuria (PKU)[1]
Pharmacology
Pharmacodynamics
- Metabolized by CYP2D6, CYP3A4, CYP2E1, CYP1A2 initially with oxidation followed by glucuronide and sulfate conjugations [1]
- Many polymorphisms with four different phenotypes
- Poor metabolizer (no functional allele)
- Intermediate metabolizer (less activity than one functional allele)
- Extensive metabolizer (two functional allele, most common phenotype)
- Ultrarapid metabolizer (three functional allele)
- Many polymorphisms with four different phenotypes
Mechanism of action
- Antagonism of the 5HT3 receptors
- Centrally, ondansetron antagonizes the 5HT3 receptors in the area postrema [1]
- Peripherally, ondansetron antagonizes the 5HT3 receptors on the vagus nerve within the GI tracts which forms synapses within the nucleus tracts solitarius [1]
- Predominant mechanism for its anti-emetic effect
Adverse effects
- Cardiac arrhythmia
- Cardiac arrest
- Constipation
- Headache
- dry mouth
- malaise
- drowsiness
- sedation
- pruritus
- transient elevation in liver function test
Pharmacokinetics
- Peak plasma concentration about 1.5 hours after an 8 mg PO dose
- Plasma half life is approximately 4 hours[2]
Chemistry and formulation
Available in PO, intramuscular (IM), and intravenous (IV).
History
References
Zabirowicz, Eric S.; Gan, Tong J. (2019), "Pharmacology of Postoperative Nausea and Vomiting", Pharmacology and Physiology for Anesthesia, Elsevier, pp. 671–692, retrieved 2023-01-05[2]
Griddine, Alexandria; Bush, Jeffrey S. (2022), "Ondansetron", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 29763014, retrieved 2023-01-05[1]
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Griddine, Alexandria; Bush, Jeffrey S. (2022), "Ondansetron", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 29763014, retrieved 2023-01-05
- ↑ 2.0 2.1 Zabirowicz, Eric S.; Gan, Tong J. (2019), "Pharmacology of Postoperative Nausea and Vomiting", Pharmacology and Physiology for Anesthesia, Elsevier, pp. 671–692, retrieved 2023-01-05
Top contributors: Cornel Chiu, Olivia Sutton and Chris Rishel